Please login to the form below

Not currently logged in
Email:
Password:

Bavarian Nordic

This page shows the latest Bavarian Nordic news and features for those working in and with pharma, biotech and healthcare.

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

AstraZeneca’s PD-L1 inhibitor Imfinzi and Bavarian Nordic’s cancer vaccine CV301 will be combined in a phase I/II trial involving patients with metastatic colorectal or pancreatic cancers. ... Copenhagen, Denmark-based Bavarian Nordic said the study

Latest news

  • Merck adds another immuno-oncology tie-up Merck adds another immuno-oncology tie-up

    The last few weeks have seen Merck KGaA subsidiary Merck Serono sign a $941m tie up with Intrexon, Novartis forge a $750m alliance with Aduro, and BMS link up with Bavarian ... Nordic and Flexus.  .

  • BMS signs $975m deal for Bavarian Nordic cancer vaccine BMS signs $975m deal for Bavarian Nordic cancer vaccine

    Furthers prominent position in immuno-oncology with Prostvac. Bristol-Myers Squibb has consolidated its position in the emerging immuno-oncology sector with a $975m deal to license Bavarian Nordic's prostate ... Furthermore, Bavarian Nordic could also

  • Ebola vaccine halt 'a precaution' say researchers Ebola vaccine halt 'a precaution' say researchers

    Meanwhile, Johnson &Johnson (J&J) is also stepping up production of its own candidate - being developed by subsidiary Crucell in partnership with the Danish biotech Bavarian Nordic and the US National

  • Dendreon files for bankruptcy protection Dendreon files for bankruptcy protection

    He also said a new prostate cancer vaccine in development at Bavarian Nordic which should be cheaper to make - could also pose a major competitive threat to Provenge.

  • J&J to produce one million doses of Ebola vaccine J&J to produce one million doses of Ebola vaccine

    The vaccine is being developed by J&J's Netherlands-based subsidiary Crucell in partnership with the Danish biotech Bavarian Nordic and the US National Institutes of Health (NIH). ... It combines Crucell's AdVac technology and Bavarian Nordi's MVA-BN

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Deal Watch December 2015 Deal Watch December 2015

    200. Bavarian Nordic (DK). Janssen. Collaboration, licence. Vaccine platform technology for development of treatment for cancers induced by HPV.

  • The world is our laboratory The world is our laboratory

    The vaccine regimen, which was discovered in a collaborative research programme with the National Institutes of Health, combines our preventative vaccine with a vaccine from Bavarian Nordic, a biotechnology company based ... Our commitment also included

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    1, 100. Bavarian Nordic / BMS. Option to license and commercialise.

  • Pharma deals in March 2015 Pharma deals in March 2015

    Fortunately, at end 2014 Bavarian Nordic was profitable and had over $175m in cash and an R&D cost of around $85m per year. ... One of Bavarian Nordic's sites is in Martinsried, the biotech cluster near Munich.

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    Identifying new agents in asthma and COPD. 196. Bavarian Nordic/J&J. Licence and supply.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics